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Abstract 
Background: The Nef protein can be detected in plasma of HIV-1-infected patients and plays a role in the pathogen-
esis of HIV-1. Nef produced during the early stages of infection is fundamental in creating the ideal environment for 
viral replication, e.g. by reducing the ability of infected cells to induce an immune response.
Aim: Based on previous experience showing that both Tat and gp41 of HIV-1 are potent chemotactic factors for 
basophils and mast cells, and gp120 is a powerful stimulus for the release of histamine and cytokines (IL-4 and IL-13) 
from basophils, in this study we aimed to verify if the HIV Nef protein can exert some effects on basophils and mast 
cells purified from healthy volunteers through the interaction with the CXCL12 receptor, CXCR4.
Methods: Basophils purified from peripheral blood cells of 30 healthy volunteers and mast cells obtained from lung 
tissue of ten healthy volunteers were tested by flow cytometric analysis, chemotaxis and chemokine production by 
ELISA assays.
Results: Nef is a potent chemoattractant for basophils and lung mast cells obtained from healthy, HIV-1 and HIV-2 
seronegative individuals. Incubation of basophils and mast cells with Nef induces the release of chemokines (CXCL8/
IL-8 and CCL3/MIP-1α). The chemotactic activity of Nef on basophils and mast cells is mediated by the interaction 
with CXCR4 receptors, being blocked by preincubation of FcεRI+ cells with an anti-CXCR4 Ab. Stimulation with Nef or 
CXCL12/SDF-1α, a CXCR4 ligand, desensitizes basophils to a subsequent challenge with an autologous or heterolo-
gous stimulus.
Conclusions: These results indicate that Nef, a HIV-1-encoded α-chemokine homolog protein, plays a direct role in 
basophils and mast cell recruitment and activation at sites of HIV-1 replication, by promoting directional migration 
of human FcεRI+ cells and the release of chemokines from these cells. Together with our previous results, these data 
suggest that FcεRI+ cells contribute to the dysregulation of the immune system in HIV-1 infection.
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Background
The human immunodeficiency viruses HIV-1 and HIV-2 
destroy CD4+ lymphocytes, thus leading to AIDS [1]. 
Entry of HIV-1 into immune cells is mediated by the viral 
envelope glycoproteins (gp120 and gp41) [2] through 
their interaction with the CD4 glycoprotein, the primary 
receptor [3], the CC chemokine receptor 5 (CCR5) and 
the CXC chemokine receptor 4 (CXCR4), obligate core-
ceptors for virus entry [2].
Viral replication and host defence escape are regulated 
by HIV-1 proteins. The accessory protein Nef, is a crucial 
determinant of viral pathogenesis and disease progres-
sion to full-blown AIDS by optimizing the cellular envi-
ronment for viral replication [4]. The key role of Nef is to 
control the expression levels of various cell surface mol-
ecules that play important roles in immunity and virus 
life cycle [5]. For example, Nef upregulates the surface 
expression of Tumor Necrosis Factor (TNF) and imma-
ture major histocompatibility complex class II (MHC-II). 
In contrast, Nef downregulates the surface expression of 
several other proteins including CD4, MHC-I, CD3, CD8, 
CD28, CXCR4, CCR5, CCR3, CD1, CD80/CD86, CTLA-
4, mature (antigenic peptide-loaded) MHC-II [6]. Nef-
mediated downregulation of MHC-I molecules, benefits 
the virus by interfering with the recognition and destruc-
tion of infected cells by cytotoxic T-cells [6]. Besides its 
well-studied effects on intracellular signaling, Nef also 
acts through its secretion in exosomes nanovesicles. Nef 
enhances exosome secretion and entry into uninfected 
CD4+ T cells, thus leading to apoptotic death [7]. Nef 
is also responsible for the inhibition of T cell migration 
in  vitro [8]. In addition, Nef affects the innate immune 
system by impairing phagocytosis, and augmenting the 
release of pro-inflammatory and chemotactic factors 
from macrophages [9]. Altogether, Nef activities support 
viral replication and survival while at the same time favor 
viral dissemination [10]. Many of these activities of extra-
cellular Nef might be mediated indirectly or directly by 
the interaction with the chemokine receptor CXCR4 [2, 
11, 12].
Basophils and mast cells are the only cells synthesizing 
histamine and expressing high affinity receptors for IgE 
(FcεRI) [13]. Immunologic activation of human basophils 
leads to the release of proinflammatory mediators and 
the synthesis of a restricted profile of cytokines (IL-4 and 
IL-13) and chemokines (CXCL8/IL-8 and CCL3/MIP-1α) 
[14, 15], while human mast cells express a wide spectrum 
of cytokines and chemokines [16, 17]. Besides being the 
effector cells of IgE-mediated responses, basophils and 
mast cells are implicated in many physiological and path-
ological processes, such as the response to infections [18, 
19], inflammatory and autoimmune diseases [20, 21] and 
cancer [22, 23].
We have investigated the role of basophils and mast 
cells in the context of HIV infection, suggesting that 
FcεRI+ cells may be a source of Th2 cytokines, thus con-
tributing to the dysregulation of the immune system 
in HIV-1. Tat protein is a potent chemoattractant for 
human basophils and mast cells by interacting with the 
α-chemokine receptor CCR3 [24]. HIV-1 envelope gp41 
peptide promotes migration of basophils and mast cells 
through interaction with formyl peptide receptors (FPRs) 
[25] and HIV-1 gp120 is a potent stimulus for IL-4 and 
IL-13 release from basophils [26, 27]. More recently, 
it has been reported that human mast cells can act as 
an inducible reservoir of persistent HIV infection [28] 
and that both mucosal mast cells and blood circulating 
basophils capture HIV-1 mediating viral trans-infection 
through the expression of multiple attachment factors 
(HAFs) [29, 30]. These findings indicate that human 
basophils and mast cells can contribute to the spread and 
persistence of HIV infection.
The results of our study further highlight the multiple 
interactions between HIV products and FcεRI+ cells and 
confirm the relevance of these cells in the promotion of 
HIV-1 infection.
Methods
Purification of peripheral blood basophils
Basophils were purified from peripheral blood cells of 
30 healthy, HIV-1 and HIV-2 seronegative, volunteers, 
aged 20–39 years (mean, 33.6 ± 4.9 years). Buffy coat cell 
packs from healthy volunteers, provided by the Hematol-
ogy Unit of the University of Salerno, were reconstituted 
in PBS containing 0.5 g/L HSA and 3.42 g/L sodium cit-
rate, and loaded onto a countercurrent elutriator (model 
J2-21; Beckman, Fullerton, CA). Several fractions were 
collected, and fractions containing large numbers of baso-
phils (>20 × 106) and of good purity (>15%) were enriched 
by discontinuous Percoll gradients [16]. Basophils were 
further purified to near homogeneity (>98%) by deplet-
ing B cells, monocytes, NK cells, dendritic cells, erythro-
cytes, platelets, neutrophils, eosinophils, and T cells with 
a cocktail of hapten-conjugated CD3, CD7, CD14, CD15, 
CD16, CD36, CD45RA, and anti-HLA-DR Abs and 
MACS MicroBeads coupled to an anti-hapten mAb. The 
magnetically labeled cells were depleted by retaining them 
on a MACS column in the magnetic field of the Midi-
MACS (Miltenyi Biotec, Bergisch Gladbach, Germany). 
Yields ranged from 3 to 10 ×  106 basophils, with purity 
usually >98%, as assessed by basophil staining with Alcian 
Blue and counting in a Spiers-Levy eosinophil counter.
Isolation and purification of human lung mast cells (HLMC)
Lung tissue was obtained from ten patients undergo-
ing thoracotomy and lung resection, after obtaining 
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their informed consent according to the guidelines of 
the institutional review board. Macroscopically normal 
parenchyma was dissected free from pleura, bronchi, and 
blood vessels and minced into a single-cell suspension as 
previously described [31]. Yields ranged between 3 × 106 
and 18 × 106 mast cells, with purity between 1 and 8%. 
Lung mast cells were purified by countercurrent elutria-
tion (J2/21; Beckman) and then by discontinuous Percoll 
density gradient as previously described [31]. Mast cells 
were further purified to near homogeneity by positive 
selection and incubation with anti-FcεRI (IgG1) followed 
by the exposure to magnetic beads coated with MACS 
goat anti-mouse IgG. Labeled cells were enriched by pos-
itive selection columns (MACS system; Miltenyi Biotec). 
The final preparations contained >95% viable cells, as 
assessed by the trypan blue exclusion method, and purity 
was >98% mast cells.
Flow cytometric analysis of surface molecules
Flow cytometric analysis of cell surface molecules was 
performed as previously described [32]. Briefly, after sat-
uration of non specific binding sites with total rabbit IgG, 
cells were incubated for 20 min at +4 °C with specific or 
isotype control antibodies. For indirect staining this step 
was followed by a second incubation for 20 min at +4 °C 
with an appropriate anti-isotype-conjugated antibody. 
Finally, cells were washed and analyzed with a FACSCali-
bur Cytofluorometer using Cell Quest software (Becton 
& Dickinson, San Fernando, CA). A total of 104 events 
for each sample were acquired in all cytofluorimetric 
analyses.
Chemotaxis assay
Basophil and mast cell chemotaxis was performed using 
a modified Boyden chamber technique as previously 
described [33]. Briefly, 25 µl of a Ca2+-containing buffer 
or various concentrations of the chemoattractants in the 
same buffer were placed in triplicate in the lower com-
partment of a 48-well microchemotaxis chamber (Neuro-
probe, Cabin John, MD). The lower compartments were 
covered with polycarbonate membranes with 5-µm pores 
(basophils) or with a two-filter sandwich constituted by 
5-µm (lower) and 8-µm (upper) pore size polycarbonate 
membranes (mast cells) (Nucleopore, Pleasanton, CA). 
Fifty microliters of the cell suspensions (5  ×  104/well) 
resuspended in a Ca2+-containing buffer was pipetted 
into the upper compartments. The chemotactic chamber 
was then incubated for 1 h (basophils) or 3 h (mast cells) 
at 37  °C in a humidified incubator with 5% CO2 (auto-
matic CO2 incubator, model 160 IR, ICN/Flow Laborato-
ries). At the end of basophil incubation, the membrane 
was removed, washed with PBS on the upper side, fixed, 
and stained with May-Grunwald/Giemsa. When mast 
cells were used, the upper polycarbonate filter was dis-
carded, while the lower nitrate cellulose filter was fixed 
in methanol, stained with Alcian Blue, and then mounted 
on a microscope slide with Cytoseal (Stephen Scientific, 
Springfield, NJ). Basophil and mast cell chemotaxis was 
quantitated microscopically by counting the number of 
cells attached to the surface of the 5-µm cellulose nitrate 
filter. In each experiment 10 fields/triplicate filter were 
measured at ×40 magnification. The results were com-
pared with buffer controls.
IL‑4, IL‑13, CXCL8/IL‑8, CCL3/MIP‑1α ELISA
IL-4, IL-13, CXCL8/IL-8, CCL3/MIP-1α release in the 
culture supernatants of basophils and HLMC cells were 
measured in duplicate determinations with a commer-
cially available ELISA kit (R&D System, Minneapolis, 
MN) [32].
Statistical analysis
The results are expressed as the mean ±  SEM. Statisti-
cal significance was analyzed by one-way ANOVA and, 
when the F value was significant, by Duncan’s multiple 
range test [34]. Differences were considered significant at 
p < 0.05.
Results
CXCR4 expression on human basophils and mast cells
Extracellular Nef exerts several functions on immune 
cells via CXCR4 receptors [11, 12, 35]. We have there-
fore investigated at protein level, by flow cytometry, the 
expression of CXCR4 on human basophils and mast cells. 
Figure. 1 shows that the vast majority of basophils (~80%) 
(Fig. 1a) and HLMC (~65%) (Fig. 1b) expressed on their 
surface the chemokine receptor CXCR4. Figure 1c shows 
the mean fluorescence intensity of CXCR4 expression in 
basophils (grey column) and HLMC cells (black column) 
over basal.
Effect of HIV‑1 r‑Nef protein on human basophil and mast 
cell chemotaxis
Having found that FcεRI+ cells expressed the chemo-
chine receptor CXCR4, we then assessed whether Nef 
was able to induce the chemotaxis of these cells. Fig-
ure 2a shows that r-Nef (3–300 ng/ml) (Abcam, Milton, 
Cambridge, UK) caused a concentration-dependent 
increase in chemotaxis of purified basophils. In a paral-
lel series of experiments we compared the chemotactic 
activity of r-Nef with that of CXCL12/SDF-1α (R&D Sys-
tem (Minneapolis, MN) and of the formylated tripeptide 
N-formyl-methionyl-leucyl-phenylalanine (fMLF) (ICN 
Biomedicals) potent chemoattractants of human baso-
phils through their interaction with the chemokine recep-
tor CXCR4 and FPR1, respectively [19, 33]. Figure  2b 
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shows that CXCL12/SDF-1α (10 and 100  ng/ml) and 
fMLF (100 and 500 ng/ml) induced strong chemotaxis of 
human basophils. In the same experiments r-Nef (10 and 
100  ng/ml) promoted comparable migratory effects on 
basophils.
Since a remarkable proportion of HLMC cells (65%) 
expressed CXCR4 receptor (Fig. 1b) and CXCR4 recep-
tor on human mast cells was functionally active being 
involved in the chemotactic response to CXCL12/
SDF-1α, we tested the chemotactic response to r-Nef of 
HLMC cells. Figure. 2c shows that r-Nef (3–300 ng/ml) 
induced a concentration-dependent increase in HLMC 
cells chemotaxis.
Checkerboard analysis was performed to discrimi-
nate between chemotaxis and nondirectional migration 
(chemokinesis) of basophils or mast cells. Cell migratory 
responses to specific stimuli were largely due to chemot-
axis and not to chemokinesis (data not shown).
Nef‑induced migration of basophils and mast cells 
through CXCR4
To establish whether the expression of CXCR4 on baso-
phils was responsible for the chemoattractant effect of 
Nef, basophils were preincubated with an anti-CXCR4 
antibody (5 μg/ml) and then assessed for their ability to 
migrate in response to Nef. Figure  3a shows that pre-
incubation of basophils with an anti-CXCR4 antibody 
(R&D System, Minneapolis, MN) (5 μg/ml) inhibited the 
chemoattractant effect of Nef. Similarly, preincubation 
of basophils with an anti-CXCR4 antibody completely 
suppressed the chemotactic activity of CXCL12/SDF-1α 
(100  ng/ml) on these cells. In contrast, the chemotac-
tic effect of fMLF (500  ng/ml), which activates a spe-
cific seven-transmembrane receptor independent of the 
CXCR4 receptor [33, 36], was not affected by the anti-
CXCR4 antibody.
We have previously demonstrated that Tat protein was 
an HIV-1-encoded α-chemokine homologous that pro-
motes basophil migration through the interaction with 
the chemokine receptor CCR3 [24]. Figure  3b demon-
strate that preincubation of basophils with anti-CCR3 
antibody (R&D System, Minneapolis, MN) (5  μg/ml) 
inhibited the chemoattractant effect of Tat (60  ng/ml). 
In contrast, the chemotactic effects of both CXCL12/
SDF-1α (100  ng/ml) and r-Nef (100  ng/ml) were not 
affected by anti-CCR3 antibody. In similar experiments, 
preincubation of mast cells with a monoclonal antibody 
against CXCR4 completely blocked the chemoattractant 
effect of Nef protein (data not shown).
Nef‑induced heterologous desensitization of CXCR4
The relationship between CXCR4 receptors and Nef 
protein was further examined using CXCL12/SDF-1α 
to induce desensitization of CXCR4-mediated func-
tions. In a first series of experiments, purified basophils 
(>98%) were incubated with buffer containing EDTA 
(4 mM), alone or in in the presence of CXCL12/SDF-1α 
(100  ng/ml) for 30  min at 37  °C. At the end of incuba-
tion, basophils were washed twice, resuspended in Ca2+-
containing buffer, and rechallenged with the chemotactic 
ba
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CXCR4 Expression 
Fig. 1 CXCR4 expression on human basophils and mast cells. a Cytofluorimetric analysis of CXCR4 expression by human basophils purified from 
normal donors, HIV-1 and HIV-2 seronegative. Basophils were incubated (25 °C, 45 min) with monoclonal anti-CXCR4 PerCP-labelled (5 µg/ml) and 
anti-IgE FITC-labelled (white histogram) or isotype-matched antibodies (grey histogram). b Cytofluorimetric analysis of CXCR4 expression by HLMC 
cells purified from normal donors, HIV-1 and HIV-2 seronegative. Mast cells were incubated (25 °C, 45 min) with monoclonal anti-CXCR4 PerCP-
labelled (5 µg/ml) and anti-IgE FITC-labelled (white histogram) or isotype-matched antibodies (grey histogram). c Mean fluorescence intensity of 
CXCR4 expression in basophils (grey column) and HLMC cells (black column) over basal
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stimuli (fMLF 500 ng/ml, CXCL12/SDF-α 100 ng/ml or 
r-Nef 100  ng/ml). Figure  4a shows that the response to 
CXCL12/SDF-1α or r-Nef was significantly reduced by 
the preincubation of cells with CXCL12/SDF-1α. By 
contrast, CXCL12/SDF-1α desensitization didn’t affect 
fMLF-dependent chemotaxis.
In a second series of experiments, purified basophils 
(>98%) were incubated with a buffer containing EDTA 
(4  mM) in the presence or absence of CXCL12/SDF-1α 
(100 ng/ml) or r-Nef (100 ng/ml) for 30 min at 37 °C. At 
the end of the incubation, basophils were washed twice, 
resuspended in a Ca2+-containing buffer, and rechal-
lenged with the chemotactic stimuli (fMLF 500  ng/ml, 
CXCL12/SDF-1α 100  ng/ml or  r-Nef 100  ng/ml). Fig-
ure 4b shows that the response to CXCL12/SDF-1α was 
significantly reduced by the preincubation with homolo-
gous or heterologous stimuli. Similarly, preincubation 
with r-Nef significantly reduced the chemotactic activ-
ity of both CXCL12/SDF-1α and r-Nef, indicating that 
the two stimuli were using the same receptor. Again, the 
chemotactic response to fMLF was unaffected by the 
desensitization with CXCL12/SDF-1α or r-Nef.
Effect of Nef on chemokine release from human basophils 
and mast cells
r-Nef upregulates mRNA for MIP-1α/MIP-1α and sev-
eral cytokines in human monocytes/macrophages [37]. 
We tested whether r-Nef could induce chemochine 
release by human basophils, which are known to release 
CXCL8/IL-8 and CCL3/MIP-1α upon immunological 
activation [38]. We therefore evaluated, at different time-
points, the release of CXCL8/IL-8 and CCL3/MIP-1α 
from basophils triggered with r-Nef. The results of three 
independent experiments showed a significant release of 
CXCL8/IL-8 after 4 h till 18 h of incubation (Fig. 5a), and 
CCL3/MIP-1α, after 4 h (Fig. 5b). Since the chemotaxis 
assay was performed after 1  h of incubation, it is likely 


























































































Fig. 2 Effect of r-Nef on chemotaxis of human basophils and mast cells. a Basophils were allowed to migrate toward r-Nef protein (3-300 ng/ml) 
for 1 h at 37 °C in the humidified incubator with 5% CO2. Values are the mean ± SEM obtained from six independent experiments with differ-
ent human basophil preparations. *p < 0.05 as compared to control. b Basophils were allowed to migrate toward the indicated concentrations 
of CXCL12/SDF-1α (white histogram), r-Nef (black histogram), and fMLF (grey histogram) for 1 h at 37 °C in a humidified incubator with 5% CO2. 
Values are the mean ± SEM obtained from four experiments. *p < 0.05 as compared to control. c HLMC cells were allowed to migrate toward r-Nef 
protein (3-300 ng/ml) for 3 h at 37 °C in the humidified incubator with 5% CO2. Values are the mean ± SEM obtained from six different experiments. 
*p < 0.05 as compared to control
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the release of chemokines from basophils. In addition 
we also evaluated the effects of increasing concentra-
tions of Nef and CXCL12/SDF-1α on cytokine (IL-4 
and IL-13) release from basophils purified from healthy 
donors. In five experiments, both r-Nef (10 and 100 ng/
ml) and CXCL12/SDF-1α (10 and 100  ng/ml) did not 
cause cytokine release from these cells (data not shown). 
We finally evaluated the kinetics of chemokine release 
induced by r-Nef from HLMC cells. Similarly to baso-
phils, r-Nef induced a significant release of CXCL8/IL-8 
at 12 and 24  h (Fig.  5c) and of CCL3/MIP-1α at 12  h 
(Fig. 5d).
Discussion
This study demonstrated that HIV-1 Nef protein is a 
chemoattractant for human basophils and mast cells 
(Fig. 2). The chemotactic activity of Nef protein was medi-
ated by the interaction with the CXCR4 receptor pre-
sent on a remarkable proportion of these cells (Figs.  1, 
3). In addition, we found that Nef induced the produc-
tion of chemokines (CXCL8/IL-8 and CCL3/MIP-1α) 
from basophils and mast cells (Fig.  5). This is the first 
demonstration that Nef protein is an HIV-1-encoded 
chemokine-homolog functionally active on human FcεRI+ 
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Fig. 3 Effect of preincubation with anti-CXCR4 and anti-CCR3 
antibody on r-Nef-dependent human basophil chemotaxis a 
Basophils were incubated with (grey histogram) or without (white 
histogram) anti-CXCR4 antibody (5 µg/ml) for 1 h, then loaded 
into the chemotaxis chamber and allowed to migrate toward the 
indicated concentrations of r-Nef, CXCL12/SDF-1α and fMLF for 1 
h at 37 °C in a humidified incubator with 5% CO2. Values are the 
mean ± SEM of three distinct experiments. *p < 0.05 as compared to 
control. b Basophils were incubated with (grey histogram) or without 
(white histogram) anti-CCR3 antibody (5 µg/ml) for 1 h, then loaded 
into the chemotaxis chamber and allowed to migrate toward the 
indicated concentrations of r-Nef, CXCL12/SDF-1α and Tat protein 
for 1 h at 37 °C in a humidified incubator with 5% CO2. Values are the 
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fMLF 
Fig. 4 Nef-induced heterologous desensitization of CXCR4. a 
Basophils were incubated with cell medium containing EDTA (4 mM) 
(white histogram) or CXCL12/SDF-1α (100 ng/ml) (grey histogram), 
for 30 min at 37 °C. At the end of incubation, basophils were washed 
twice, resuspended in Ca2+-containing buffer, and rechallenged with 
the chemotactic stimuli fMLF (500 ng/ml), CXCL12/SDF-1α (100 ng/
mL), or r-Nef protein (100 ng/ml). *p < 0.05 as compared to control. b 
Basophils were incubated with cell medium containing EDTA (4 mM) 
(white histogram), fMLF (500 ng/ml) (light grey histogram), CXCL12/
SDF-1α (100 ng/ml) (black histogram) or r-Nef protein (100 ng/ml) 
(grey histogram), for 30 min at 37 °C. At the end of incubation, cells 
were washed twice, resuspended in Ca2+-containing buffer, and 
challenged with the chemotactic stimuli CXCL12/SDF-1α (100 ng/
ml) or r-Nef (100 ng/ml). Values are the mean ± SEM of three distinct 
experiments. *p < 0.05 as compared to basophils preincubated in the 
absence of chemotactic stimuli
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It is well known that CXCR4 is a co-receptor for several 
strains of HIV-1 [39]. Here we demonstrated that soluble 
r-Nef specifically interacts with CXCR4 on human baso-
phils and mast cells. Indeed, a monoclonal antibody anti-
CXCR4 completely blocked the chemoattractant effect of 
Nef protein (Fig. 3). The specificity of this interaction was 
confirmed by the observation that preincubation of cells 
with anti-CCR3 antibody did not modify the chemotac-
tic response of both r-Nef and CXCL12/SDF-1α (Fig. 3). 
Finally, the cross-desensitization of basophil chemotaxis 
with Nef provided the evidence that Nef interacts with 
the CXCR4 receptor on human FcεRI+ cells (Fig. 4).
These findings are relevant at different levels. Firstly, 
they suggest that during HIV-1 infection, Nef can influ-
ence the directional migration of human basophils and 
mast cells, thus contributing to the recruitment of these 
cells at sites of HIV-1 infection. Secondly, the chemo-
tactic activity of Nef on human FcεRI+ cells might con-
tribute to increase the local density of mast cells and 
basophils available for HIV-1 interaction through the 
virus-bound or shed gp120. In fact, we have previously 
demonstrated that gp120 from different clades interacts 
with the IgE VH3+ present on human FcεRI+ [26]. The 
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Fig. 5 Effects of r-Nef on CXCL8/IL-8 and CCL3/MIP-1α release from human basophils and mast cells. a 106 purified basophils/sample were incu-
bated for 4 or 18 h without (white histogram) or with r-Nef (100 ng/ml) (grey histogram). Supernatants were collected at each time point. CXCL8/
IL-8 was determined by ELISA. Values are the mean ± SEM of three distinct experiments. *p < 0.05 as compared to basophils preincubated in the 
absence of chemotactic stimuli. b 106 purified basophils/sample were incubated for 4 or 18 h without (white histogram) or with r-Nef (100 ng/
ml) (grey histogram). Supernatants were collected at each time point. CCL3/MIP-1α was determined by ELISA. Values are the mean ± SEM of three 
distinct experiments. *p < 0.05 as compared to basophils preincubated in the absence of chemotactic stimuli. c 106 HLMC cells/sample were 
incubated for 12 or 24 h without (white histogram) or with r-Nef (100 ng/ml) (grey histogram). Supernatants were collected at each time point. 
CXCL8 was determined by ELISA. Values are the mean ± SEM of three distinct experiments. *p < 0.05 as compared to mast cells preincubated in the 
absence of chemotactic stimuli. d 106 HLMC cells/sample were incubated for 12 or 24 h without (white histogram) or with r-Nef (100 ng/ml) (grey 
histogram). Supernatants were collected at each time point. CCL3/MIP-1α was determined by ELISA. Values are the mean ± SEM of three distinct 
experiments. *p < 0.05 as compared to mast cells preincubated in the absence of chemotactic stimuli
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to the rapid synthesis and release of IL-4 and IL-13 from 
human FcεRI+ cells [18]. This interaction might rep-
resent an initial source of cytokines, thereby favoring 
a shift from a Th0 toward a Th2 phenotype. The latter 
observation is relevant because HIV-1 is known to rep-
licate preferentially in Th2 cells [40]. Finally, mast cells 
and basophils rectruited at the site of HIV infection can 
directly contribute to the spread of the infection by act-
ing as virus reservoir and mediating trans-infection of 
CD4+ T cells, as recently demonstrated [28, 30].
The clinical relevance of our findings is confirmed by 
the observation that Nef was present in the serum of 
HIV-1-infected patients at concentrations as high as 
10  ng/ml [41]. In tissues where viral replication occurs 
(e.g. the lymph nodes), local levels of Nef could exceed 
those found in serum. Because the early phases of infec-
tion are associated with high levels of viremia [1], and 
this, in turn, may be associated with high levels of Nef, 
chemokine-like activity of Nef on FcεRI+ cells might be 
of clinical relevance in patients with HIV-1 infection.
Intriguingly, many viruses exploit the strategy of using 
homologs of cellular cytokines and chemokines to shield 
virus-infected cells from immune defenses and enhance 
virus survival in the host [42, 43]. The existence of these 
virus-encoded homologs of cellular proteins is indirect 
evidence of their relevant role in orchestrating the host 
immune response to invading pathogens [43]. Many 
large DNA viruses, including CMV and HHV-8, as well 
as the poxvirus Molluscum contagiosum, encode sev-
eral α-chemokine homologs (virokines) acting on CCR3 
or CCR8 receptors [44–46]. This novel observation may 
have several implications for a better understanding of 
the pathogenesis of HIV-1 infection.
In conclusion, we provided the first evidence that Nef 
protein is an HIV-1-encoded chemokine-homolog able 
to activate human FcεRI+ cells, by interacting with the 
CXCR4 receptor on these cells. Because HIV-1 enters 
the body predominantly through mucosal surfaces and 
because early phases of infection are associated with high 
levels of viremia, both mast cells, in tissues, and baso-
phils, in circulation, can be exposed to high local levels 
of Nef protein, which in turns induce their recruitement 
and activation in sites of infection. Overall, our results 
suggests a novel mechanism through which FcεRI+ cells 
can contribute to the dysregulation of the immune sys-
tem in HIV-1 infection.
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